Aptiom
(Eslicarbazepine acetate)Phase 3Small molecule
Sumitomo Pharma America, Inc.Eslicarbazepine acetate is used to treat epilepsy by helping to control seizures in the brain. It can be used alone or combined with other seizure medications.[1] Aptiom is currently being investigated across 11 indications[3], with its most advanced program in Phase 3.[1]
Aptiom is one of 302 small molecule programs targeting Neuropathic Pain. It is currently in Phase 3.
11
Indications
26
Total Trials
0
Active Trials
301
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
221 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Briviact
UCBPhase 3
Aptiom
Sumitomo Pharma America, Inc.Phase 3
Epidiolex
Jazz PharmaceuticalsPhase 3
Depacon
AbbViePhase 3
Dayvigo
EisaiPhase 3
Zonegran
AAzurity Pharmaceuticals
Phase 3
Actemra
RochePhase 3
Fintepla
IImmedica Pharma AB
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Narcan
SScienture
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Seizure7 trials
Show 4 more trials
Partial Epilepsy4 trials
Neuralgia2 trials
Bipolar I Disorder2 trials
10 more indications
Statin1 trial
Metformin1 trial
Diabetic Neuropathy1 trial
Interaction1 trial
Tics1 trial
Adolescent1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Eslicarbazepine acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details